Juvenile Huntington Disease

Juvenile Huntington Disease (JHD) is a rare and severe form of Huntington’s disease that begins before the age of twenty. Huntington’s disease itself is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin (HTT) gene, which eventually leads to progressive damage of nerve cells in the brain (National Institute of Neurological Disorders and Stroke, 2025). Although Huntington’s disease is most prevalent and commonly diagnosed in adults between the ages of thirty to fifty, approximately 5-10% of cases appear during childhood or adolescence (GARD, 2016). 

JHD is often more severe than adult-onset Huntington’s disease. Many children with JHD may often face movement problems, learning difficulties, emotional changes, and even seizures (Cleveland Clinic, 2023). Unfortunately, this disease is rare which means that researchers are still studying for ways to improve treatment and care for those that are affected by JHD. 

JHD is caused by a mutation in the HTT gene on chromosome four (Ajitkumar & De Jesus, 2023). The mutation involves expanded CAG repeats in the gene and larger repeat expansions are linked to earlier disease onset and more severe symptoms. CAG repeats are the sequential repetition of the DNA triplet, cytosine, adenine, and guanine within a specific gene. (Paulson, 2018).

The disease is inherited in an autosomal dominant pattern. This indicates that a child will only need one affected parent to inherit the disorder. Each child of an affected parent has a fifty percent chance of inheriting the mutation (Cleveland Clinic, 2023). Many juvenile cases are inherited from the father due to genetic anticipation. This occurs when the number of CAG repeats increases from one generation to the next. The abnormal huntingtin protein then slowly damages neurons in the brain (GARD, 2016).

JHD affects movement, thinking, and behavior. Some of the more common symptoms that involve motor behavior include muscle stiffness, tremors, poor coordination, and difficulty with walking (Juvenile Onset HD , n.d.). There may also be chances of speech and swallowing problems developing. Cognitive symptoms, on the other hand, often include memory loss, trouble with concentrating, and a decline in school performance. Many children struggle academically as the disease progresses (Cleveland Clinic, 2023). Many psychiatric symptoms are also common. Patients may experience depression, anxiety, aggression, and many mood swings. Seizures tend to occur more often in JHD than in adult-onset Huntington’s disease (Joanna Quigley, 2016). Overall, the main difference that JHD has from adult-onset Huntington disease is that patients experience more rigidity and seizures, faster disease progression, and a greater effect on learning and development.

Diagnosing JHD can be difficult because most of the symptoms often resemble other neurological disorders. Doctors usually begin with a neurological exam and look into family medical history (Ajitkumar and De Jesus, 2023). Genetic testing then confirms whether the HTT mutation is present. Brain imaging tests such as the MRI scans also play a role in helping identify brain degradation (Cleveland Clinic, 2023).

Additionally, doctors may perform cognitive and psychological evaluations. It is crucial for families to get early diagnosis in order for them to receive accessible treatment, counseling, and support services as soon as possible. 

After diagnosis for JHD, treatment options may vary. As of right now, there is currently no cure for JHD. Most treatment options focus on managing symptoms and improving the overall quality of life for patients. Doctors may prescribe medications for symptoms such as depression, seizures, anxiety, and muscle stiffness (Ajitkumar and De Jesus, 2023). Physical therapy and occupational therapy allows patients to maintain movement and improve daily functioning. Speech and nutritional therapy is an option for patients, as some eventually require feeding tubes because of swallowing difficulties. It is important for families to make use of counseling and support groups in order to receive many benefits. Schools may even provide accommodations to help those students impacted manage learning difficulties (Huntington’s Disease Therapy, n.d.).

JHD has a major impact on both patients and families in many ways, both socially and psychologically. Children may face depression, frustration, and social isolation. Parents and caregivers may experience struggles with emotional distress and financial issues. Furthermore, siblings can struggle with fear and uncertainty about the disease. As for socially, school difficulties are common because of declining cognitive and motor abilities (Lindo et al., 2025). 

The good news is that researchers are continuing to work and search for better treatments for Huntington’s disease. Gene therapy and RNA-targeting treatments are currently being studied (Ferguson et al., 2022). Scientists are also exploring CRISPR gene-editing technology. These experimental approaches may one day slow or stop disease progression. Researchers hope that future discoveries will lead to earlier diagnosis, better symptom management, and eventually a cure.

Juvenile Huntington’s Disease is a rare but devastating neurological disorder that is not talked about enough. The disease can heavily affect an individual in several ways, such as movement, thinking, emotions, and their overall quality of life. Although there is no cure yet, supportive treatments and therapies can help families and patients manage symptoms and stay strong during difficult moments. Continued research and awareness are crucial for improving future medical care and treatment options for this disease. 

---

Works Cited:

Ajitkumar, A., & De Jesus, O. (2023). Huntington Disease. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559166

Cleveland Clinic. (2023, September 27). Huntington’s Disease. Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/14369-huntingtons-disease

Ferguson, M. W., Kennedy, C. J., Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022). Current and possible future therapeutic options for huntington’s disease. Journal of Central Nervous System Disease, 14. https://doi.org/10.1177/11795735221092517

GARD. (2016). Juvenile Huntington disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. Nih.gov. https://rarediseases.info.nih.gov/diseases/10510/juvenile-huntington-disease

Huntington’s Disease Therapy. (n.d.). Www.theraplatform.com. https://www.theraplatform.com/blog/951/huntington-s-disease-therapy

Joanna Quigley, M. D. (2016). Juvenile Huntington Disease: Rare But With Psychiatric Implications. Www.psychiatrictimes.com. https://www.psychiatrictimes.com/view/juvenile-huntington-disease-rare-psychiatric-implications

Juvenile Huntington disease (Concept Id: C0751208) - MedGen - NCBI. (2016). Nih.gov. https://www.ncbi.nlm.nih.gov/medgen/155518

Juvenile Onset HD | Huntington’s Disease Society of America. (n.d.). Huntington’s Disease Society of America. https://hdsa.org/what-is-hd/history-and-genetics-of-huntingtons-disease/juvenile-onset-hd/

Lindo, P., Tindall, T., Buswell, S., Lock, S., & Gunn, S. (2025). Psychosocial Impacts of Huntington’s Disease on Individuals, Relatives and Family Systems: A Thematic Synthesis. Clinical Genetics. https://doi.org/10.1111/cge.70102

National Institute of Neurological Disorders and Stroke. (2025, April 8). Huntington’s Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease

Paulson, H. (2018). Repeat Expansion Diseases. Neurogenetics, Part I, 147, 105–123. https://doi.org/10.1016/b978-0-444-63233-3.00009-9